Fludarabine
Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)Small moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 81/ 100
Competitive context
54 Active assets in the Angioimmunoblastic T-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide Shandong Provincial Hospital | Phase 4 | BBB |
DEXAMETHASONE Ou Bai, MD/PHD | Phase 2 | BB |
Romidepsin The Lymphoma Academic Research Organisation | Phase 3 | BB |
PREDNISONE TABLETS Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
ETOPOSIDE Eric Jacobsen, MD | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →